News

Covid-X Open Call to defeat COVID-19/Corona clinical challenges

Published on | 5 years ago

Programmes ICT Health

COVID-X, an exclusive acceleration program funded by the European Union to defeat COVID-19 clinical challenges through the power of data, has launched the Open Call #1 for European Tech Companies with outstanding Data Technology solutions that can overcome COVID-19 clinical challenges and save lives. This Open Call is also addressed for healthcare providers dealing with coronavirus patients and validating the solutions in real care environments. 

Funding: 100.000€ (single player) to validate data solutions with a clinical partner - 150.000€ (team players) to validate the solution (tech companies and healthcare providers)

Deadline: 27.01.2021

All details on www.covid-x.eu 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1784 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.